Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions

doi:10.3748/wjg.v23.i9.1618

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14908)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

611

WORD

241

HTML

10966

Figures (1-1)

359

Tables (1-4)

238

Sum=12415

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

769

Download

1724

Sum=2493

Mar 7, 2017 (publication date) through Feb 9, 2025

Times Cited of This Article

Times Cited (39)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 7, 2017; 23(9): 1618-1626
Published online Mar 7, 2017. doi: 10.3748/wjg.v23.i9.1618

Table 2 Drug-drug interactions identified from baseline medication list

Regimen	n = 664	Total number of meds	Total number of interactions, n (%)	Average number of meds per patient	Average number of interactions per patient	Contra-indications
LDV/SOF	369	2996	472 (15.8)	8.12	1.28	7
OBV/PTV/r + DSV	48	312	119 (38.1)	6.50	2.48	4
SIM/SOF	114	1002	169 (16.8)	8.79	1.48	19
SOF/RBV	133	964	21 (2.2)	7.25	0.16	1

LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV: Paritaprevir; DSV: Dasabuvir; SIM: Simeprevir; RBV: Ribavirin.

Citation: Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23(9): 1618-1626
URL: https://www.wjgnet.com/1007-9327/full/v23/i9/1618.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i9.1618